论文部分内容阅读
目的:探讨阿托伐他汀对急性冠脉综合征(ACS)患者血清妊娠相关蛋白-A(PAPP-A)和C反应蛋白(CRP)的影响。方法:选取ACS患者(ACS组)105例和正常对照组90例,测定其PAPP-A及CRP水平,将105例ACS患者随机分阿托伐他汀20mg组(高剂量组,51例)和阿托伐他汀10mg组(低剂量组,54例),分别采用20mg和10mg阿托伐他汀治疗1周后,再次测定PAPP-A及CRP水平。结果:ACS组血清PAPP-A和CRP水平高于对照组,差异有统计学意义(P<0.01)。治疗前,高剂量组和低剂量组的PAPP-A及CRP水平差异无统计学意义,治疗后高剂量组和低剂量组的PAPP-A及CRP水平均低于治疗前,治疗后高剂量组的PAPP-A及CRP水平均低于低剂量组,差异均有统计学意义(P<0.01)。结论:阿托伐他汀可以减轻ACS患者的炎症反应,稳定冠脉粥样硬化斑块。
Objective: To investigate the effect of atorvastatin on serum pregnancy-associated protein-A (PAPP-A) and C-reactive protein (CRP) in patients with acute coronary syndrome (ACS). Methods: 105 patients with ACS (ACS group) and 90 normal controls were enrolled in this study. The levels of PAPP-A and CRP were determined. A total of 105 ACS patients were randomized into 20 mg atorvastatin group (high dose group, n = 51) Atorvastatin 10mg group (low dose group, 54 cases), respectively, after 20mg and 10mg atorvastatin treatment for 1 week, re-determination of PAPP-A and CRP levels. Results: The levels of serum PAPP-A and CRP in ACS group were significantly higher than those in control group (P <0.01). There was no significant difference in PAPP-A and CRP levels between high-dose group and low-dose group before treatment, and the levels of PAPP-A and CRP in high-dose group and low-dose group after treatment were lower than those before treatment and after high-dose treatment The PAPP-A and CRP levels were lower than the low-dose group, the difference was statistically significant (P <0.01). Conclusion: Atorvastatin can reduce the inflammatory response in ACS patients and stabilize the coronary atherosclerotic plaque.